Right now, more than 17 potential treatments are in Phase 3 clinical trials, and leading researchers are optimistic that promising new drugs will reach the market in the next five years.
This is big news: These would be the first new therapies on the market in over a decade!
Drew Holzapfel, Director of ResearchersAgainstAlzheimer’s, and Dr. David Morgan, CEO of the Byrd Alzheimer’s Institute at the University of South Florida, know the details of the coming wave of drugs inside and out. These gentlemen will join this month’s UsAgainstAlzheimer’s Alzheimer’s Talks to answer your questions about the growing hope for a cure.
Join the call on Monday, April 11, from 4 to 5 p.m. ET for a fascinating conversation about new Alzheimer’s drugs in the pipeline! Thank you to UsAgainstAlzheimer’s and ResearchersAgainstAlzheimer’s for making this call possible!!